David Lebwohl has sold NTLA and made no open-market buys since Aug 2021

David Lebwohl, M.D. is the Executive Vice President and Chief Medical Officer at Intellia Therapeutics, Inc. (NTLA), a biotechnology company developing CRISPR/Cas9-based therapies for immuno-oncology, autoimmune diseases, and other conditions.( He recently engaged in insider trading at NTLA and is set to retire effective August 7, 2026, while continuing in his role until a successor is appointed.(

Dr. Lebwohl earned an undergraduate degree in Biochemical Sciences from Harvard College and a Doctor of Medicine from Yale University School of Medicine, followed by training in internal medicine, hematology, and medical oncology at Brigham and Women’s Hospital and Memorial Sloan-Kettering Cancer Center.( His career highlights include roles at Bristol Myers Squibb as Group Director of Clinical Oncology, and at Novartis from 2002, where he led development of Afinitor (five approvals) and Kymriah (first global CAR-T approval).( Before Intellia, he served as CMO at Semma Therapeutics (acquired by Vertex).(

Written by Perplexity from public sources.